Compounds > ecteinascidin 743
Page last updated: 2024-09-02

ecteinascidin 743 and mitomycin

ecteinascidin 743 has been researched along with mitomycin in 5 studies

Compound Research Comparison

Studies
(ecteinascidin 743)		Trials
(ecteinascidin 743)		Recent Studies (post-2010)
(ecteinascidin 743)		Studies
(mitomycin)		Trials
(mitomycin)		Recent Studies (post-2010) (mitomycin)
66010240412,8931,7382,808

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (20.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Corey, EJ; Martinez, EJ; Owa, T; Schreiber, SL1
Albella, B; Bueren, JA; Casado, JA; Domingo, A; Gago, F; García-Hernández, V; Marco, E; Pérez, L; Río, P; Tercero, JC; Vaquero, JJ1
Bueren-Calabuig, JA; Egly, JM; Gago, F; Galmarini, CM; Giraudon, C1
Albella, B; Aracil, M; Bueren, JA; Gago, F; Galmarini, CM; Martínez, S; Pérez, L; Tercero, JC1

Other Studies

5 other study(ies) available for ecteinascidin 743 and mitomycin

ArticleYear
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Phthalascidin, a synthetic antitumor agent with potency and mode of action comparable to ecteinascidin 743.
    Proceedings of the National Academy of Sciences of the United States of America, 1999, Mar-30, Volume: 96, Issue:7

    Topics: Antineoplastic Agents, Alkylating; Bleomycin; Camptothecin; Cell Division; Cisplatin; Cross-Linking Reagents; Dioxoles; DNA Topoisomerases, Type I; DNA, Neoplasm; Doxorubicin; Etoposide; Female; Humans; Isoquinolines; Male; Mitomycin; Models, Molecular; Molecular Structure; Neoplasm Proteins; Paclitaxel; Phthalimides; Structure-Activity Relationship; Tetrahydroisoquinolines; Trabectedin; Tumor Cells, Cultured

1999
Relevance of the Fanconi anemia pathway in the response of human cells to trabectedin.
    Molecular cancer therapeutics, 2008, Volume: 7, Issue:5

    Topics: Antineoplastic Agents, Alkylating; Cell Cycle; Dioxoles; DNA; DNA Breaks, Double-Stranded; DNA Repair; Dose-Response Relationship, Drug; Fanconi Anemia; Fanconi Anemia Complementation Group Proteins; Humans; Mitomycin; Tetrahydroisoquinolines; Time Factors; Trabectedin

2008
Temperature-induced melting of double-stranded DNA in the absence and presence of covalently bonded antitumour drugs: insight from molecular dynamics simulations.
    Nucleic acids research, 2011, Volume: 39, Issue:18

    Topics: Antineoplastic Agents; Base Pairing; Cross-Linking Reagents; Dioxoles; DNA; Hydrophobic and Hydrophilic Interactions; Mitomycin; Molecular Dynamics Simulation; Nucleic Acid Denaturation; Temperature; Tetrahydroisoquinolines; Trabectedin

2011
Inhibitory effects of marine-derived DNA-binding anti-tumour tetrahydroisoquinolines on the Fanconi anaemia pathway.
    British journal of pharmacology, 2013, Volume: 170, Issue:4

    Topics: Animals; Antineoplastic Agents; Binding Sites; Carbolines; Cell Line, Tumor; Dioxoles; DNA; Dose-Response Relationship, Drug; Fanconi Anemia; Fanconi Anemia Complementation Group Proteins; Hematopoietic Stem Cells; Heterocyclic Compounds, 4 or More Rings; Humans; Mice; Mice, 129 Strain; Mice, Inbred BALB C; Mice, Transgenic; Mitomycin; Neoplasms; Signal Transduction; Tetrahydroisoquinolines; Trabectedin

2013